Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Camidge · SciRah

Researcher profile · Semantic Scholar

D. Camidge

Share profile

D. Camidge — researcher profile on SciRah

h-index: 87
Works: 666
Citations: 45K

Most-cited papers

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
F. Skoulidis, Haniel A. Araujo, Minh Truong Do, Yu Qian +127 more
2024Nature197 citations Open access
Semantic Scholar
Repotrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
A. Drilon, D. Camidge, J. Lin, Sang-we Kim +29 more
2024New England Journal of Medicine187 citations Open access
Semantic Scholar
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita S. Lopez, T. Powles, F. Braiteh, L. Siu +76 more
2025Nature Medicine104 citations Open access
Semantic Scholar
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J. Lin, J. C. Horan, A. Tangpeerachaikul, A. Swalduz +24 more
2024Cancer Discovery51 citations Open access
Semantic Scholar
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib.
H. Horinouchi, B. Cho, D. Camidge, K. Goto +9 more
2025Annals of Oncology50 citations Open access
Semantic Scholar
Tyrosine Kinase Inhibitors with and without Upfront Stereotactic Radiosurgery for Brain Metastases from EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC)
L. Pike, E. Miao, Lillian A. Boe, T. Patil +20 more
2024Journal of Clinical Oncology49 citations Open access
Semantic Scholar
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.
Charu Aggarwal, A. Martínez-Martí, M. Majem, F. Barlesi +13 more
2025JAMA Network Open32 citations Open access
Semantic Scholar
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy.
William J. Phillips, D. Camidge, P. Wheatley-Price
2025Journal of Thoracic Oncology19 citations Open access
Semantic Scholar
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
A. Drilon, J. Lin, M. Johnson, C. Baik +16 more
2024Annals of Oncology19 citations
Semantic Scholar
1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
B. Besse, A. Drilon, B. C. Cho, D. Camidge +16 more
2024Annals of Oncology18 citations
Semantic Scholar
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
A. Nassar, Chul Kim, T. Adeyelu, Elias J. Bou-Farhat +70 more
2025Nature Communications17 citations Open access
Semantic Scholar
Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR -mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.
D. Camidge, J. Raimbourg, Yun-Gyoo Lee, M. D. de Miguel +16 more
2025Journal of Clinical Oncology17 citations
Semantic Scholar
Mobocertinib: Mechanism of action, clinical, and translational science
M. Hanley, D. Camidge, R. J. Fram, Neeraj Gupta
2024Clinical and Translational Science16 citations Open access
Semantic Scholar
Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.
D. Camidge, J. Bar, H. Horinouchi, J. Goldman +16 more
2024Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).
F. Barlesi, E. Felip, Sanjay Popat, B. Solomon +10 more
2024Journal of Clinical Oncology13 citations
Semantic Scholar
1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
M. D. de Miguel, N. Yamamoto, J. Raimbourg, B. C. Cho +13 more
2024Annals of Oncology12 citations Open access
Semantic Scholar
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Cai-Cun Zhou, L. Greillier, Geoffrey Liu, Thomas John +26 more
2026New England Journal of Medicine11 citations
Semantic Scholar
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).
Charu Aggarwal, A. Martínez-Martí, M. Majem, F. Barlesi +12 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
A. Drilon, B. C. Cho, J. Lin, B. Solomon +33 more
2025Journal of Thoracic Oncology10 citations Open access
Semantic Scholar
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
Byoung Chul Cho, Melissa L. Johnson, J. Bar, E. Schaefer +17 more
2025Lung Cancer9 citations Open access
Semantic Scholar
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial
N. Girard, J. Goldman, Shun Lu, J. Bar +23 more
2026JTO Clinical and Research Reports6 citations Open access
Semantic Scholar
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Yan Xu, J. Yang, Yan-Qiu Zhao, L. Doucet +46 more
2025Cell Reports Medicine6 citations Open access
Semantic Scholar
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
A. Barsouk, O. Elghawy, A. Watts, L. Reed-Guy +25 more
2025Lung Cancer6 citations Open access
Semantic Scholar
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
J. Bar, Emilio Esteban, D. Rodríguez-Abreu, S. Aix +19 more
2024Lung Cancer6 citations Open access
Semantic Scholar
PPD01.07 Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC
J. Rotow, G. Dy, D. Camidge
2024Journal of Thoracic Oncology6 citations Open access
Semantic Scholar
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer
J. Bar, Mona Cai, Yookyung Chrisrty Choi, S. Baijal +10 more
2025Acta oncologica5 citations Open access
Semantic Scholar
LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR -wildtype advanced NSCLC: Efficacy outcomes by prior therapy.
J. Goldman, Shun Lu, J. Bar, H. Horinouchi +11 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
D. Camidge, Shunichi Sugawara, Masashi Kondo, Hye Ryun Kim +13 more
2025Lung Cancer5 citations Open access
Semantic Scholar
103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
F. Barlési, E. Felip, S. Popat, B. Solomon +10 more
2024ESMO Open5 citations Open access
Semantic Scholar
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
F. Skoulidis, Haniel A. Araujo, Minh Truong Do, Yu Qian +127 more
2025Nature4 citations Open access
Semantic Scholar
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study
E. Adib, A. H. Nassar, Katie N Lee, Francesca Fusco +25 more
2025JTO Clinical and Research Reports4 citations Open access
Semantic Scholar
The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.
William J. Phillips, Alexander S Watson, D. Camidge
2024Journal of Thoracic Oncology4 citations Open access
Semantic Scholar
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Lyudmila Bazhenova, J. Hodgson, D. Camidge, Corey J. Langer +12 more
2025Clinical Lung Cancer3 citations Open access
Semantic Scholar
Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype ( EGFR wt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE).
D. Camidge, Shun Lu, J. Goldman, H. Horinouchi +11 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
Jürgen Wolf, Sarah Goring, Adam Lee, B. C. Cho +10 more
2025Cancers3 citations Open access
Semantic Scholar
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer.
Alexander S. Watson, Harris Krause, A. Elliott, A. Farrell +7 more
2024Clinical Lung Cancer3 citations
Semantic Scholar
Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC.
Y. Goto, C. Baik, F. Cappuzzo, D. Camidge +13 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
David Tsui, Jessica K. Lee, C. B. Tambaoan, J. Hughes +5 more
2025Lung Cancer2 citations Open access
Semantic Scholar
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors
Alexander S. Watson, Alyse W. Staley, B. Yoder, Sean J. Iwamoto +5 more
2025JTO Clinical and Research Reports2 citations Open access
Semantic Scholar
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101
Nicolas Girard, Qingqing Xu, D. Camidge, S. Baijal +7 more
2025The Oncologist2 citations Open access
Semantic Scholar
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.
D. Camidge, N. Girard, Shun Lu, S. Gadgeel +14 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
MA02.03 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Long-Term Follow-Up From the Phase 1/2 TRIDENT-1 Trial
B. Cho, J. Lin, D. Camidge, M. Nagasaka +20 more
2025Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
98P: Exploratory analysis showed increased overall survival among non-small cell lung cancer (NSCLC) patients with mutated KRAS compared with wildtype KRAS in a phase II trial of mecbotamab vedotin (CAB-AXL-ADC)
K. Reckamp, G. Dy, E. Yau, J. Rotow +16 more
2025Journal of Thoracic Oncology2 citations
Semantic Scholar
Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer
M. V. von Itzstein, T. Burns, J. Dowell, L. Horn +12 more
2024Clinical Cancer Research2 citations Open access
Semantic Scholar
Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.
A. Drilon, R. Dziadziuszko, D. Camidge, J. Lin +16 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
1379P c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study
J. Bar, S. Baijal, A. Luo, N. Zhang +4 more
2024Annals of Oncology2 citations
Semantic Scholar
High PD-L1 expression among patients with ALK rearranged non–small cell lung cancer and response to first line ALK tyrosine kinase inhibitors.
Yu-Nan Nie, Alyse W. Staley, T. Hinz, D. Merrick +6 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).
M. V. von Itzstein, T. Burns, J. Dowell, L. Horn +6 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration.
Y. Piña, Maxine Umeh Garcia, A. Boire, A. Brenner +19 more
2026Neuro-Oncology1 citations Open access
Semantic Scholar
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
A. Drilon, B. C. Cho, D. Camidge, Misako Nagasaka +17 more
2026The Oncologist1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Besse×10
Invite
B. Besse — researcher profile on SciRah
A. Drilon×9
Invite
A. Drilon — researcher profile on SciRah
J. Bar×8
Invite
J. Bar — researcher profile on SciRah
J. Goldman×7
Invite
J. Goldman — researcher profile on SciRah

×7

Invite

C. Ratajczak — researcher profile on SciRah

Jürgen Wolf×5

Invite

Jürgen Wolf — researcher profile on SciRah

Misako Nagasaka×5

Invite

Misako Nagasaka — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah

M. Moskovitz×5

Invite

M. Moskovitz — researcher profile on SciRah

H. Horinouchi×5

Invite

H. Horinouchi — researcher profile on SciRah

Invite

Shun Lu — researcher profile on SciRah